Anphar Laboratories

What Anphar Laboratories does

Anphar Laboratories Pvt. Ltd. is a privately held Indian pharmaceutical company founded in 1987 and headquartered in Jammu & Kashmir, specializing in the development, production, and export of Active Pharmaceutical Ingredients (APIs), impurities and reference standards, and advanced drug intermediates. The company holds WHO-GMP and ISO 9001 certifications and operates a portfolio of approximately 25 APIs spanning antipsychotics (Haloperidol, Amisulpride, Trifluoperazine, Fluphenazine), antidepressants (Paroxetine, Fluvoxamine, Amoxapine), antiemetics (Metoclopramide, Prochlorperazine), NSAIDs (Benzydamine), antihistamines (Ebastine), DMARDs/bisphosphonates (Leflunomide, Risedronate Sodium), and specialty molecules (Citicoline, Acamprosate, Pantoprazole). Products are manufactured to IP, BP, USP, and EP pharmacopoeial standards in state-of-the-art facilities equipped with HPLC and GC analytical instruments.

The company's business model is B2B direct sales to pharmaceutical manufacturers and distributors, with all revenue generated through custom-priced, multi-year contracts. Its revenue streams include API sales (one-time license supply), impurities and working standards, advanced drug intermediates, and Contract Research and Manufacturing Services (CRAMS). Anphar exports to over 40 countries across Europe, Latin America, Africa, and Asia, with a documented enterprise customer base that includes Cadila Pharmaceuticals, Square Pharmaceuticals, Akums Drugs & Pharmaceuticals, Coral Labs, Medicamen Biotech, Nabi Qasim, Gedanum Pharma, INFA GmbH, and AL Andalous. The company is founder-led, with Anil Gupta serving as Founder & Managing Director alongside his son Ankit Gupta as Director and Neeru Dulloo as Executive Director; no institutional investors or external funding have been disclosed.

The company maintains an R&D function focused on novel therapeutics and process improvement, with capabilities in impurity identification and characterization that serve both internal API production and external reference-standard supply. Go-to-market relies on direct enterprise sales, a company website with inquiry forms, LinkedIn and other social channels, and participation in pharmaceutical industry events. No AI/ML, software, or digital platform capabilities are disclosed in the available data.

Name

Anphar Laboratories

Legal name

Anphar Laboratories Pvt. Ltd.

Website

https://anphar.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

51–100 employees

Short description

Anphar Laboratories is a privately held Indian API manufacturer founded in 1987, producing WHO-GMP certified Active Pharmaceutical Ingredients, impurities, and drug intermediates for global pharmaceutical companies across 40+ countries.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industry

Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical API manufacturing
• Advanced drug intermediates
• Pharmaceutical impurities standards
• Contract manufacturing services

Headquarters

HQ city

Jammu

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Development, production, and marketing of high-quality APIs across multiple therapeutic categories including antipsychotics, antidepressants, antiemetics, anti-inflammatory, antihistamines, and bone health medications
2. Impurities and Working Standards: Specialized identification, isolation, and characterization of pharmaceutical impurities and reference standards for quality control and regulatory compliance
3. Advanced Drug Intermediates: Manufacturing and supply of advanced drug intermediates supporting in-house API production and serving other pharmaceutical manufacturers worldwide
4. CRAMS (Contract Research and Manufacturing Services): Customized, efficient, and cost-effective contract research and manufacturing services delivered through state-of-the-art facilities and experienced scientific team

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Anphar Laboratories develops, manufactures, and exports Active Pharmaceutical Ingredients (APIs) across multiple therapeutic categories along with pharmaceutical impurities and reference standards, advanced drug intermediates, and Contract Research and Manufacturing Services (CRAMS). The company supplies 25+ APIs such as Haloperidol, Amisulpride, Paroxetine, Fluvoxamine, Metoclopramide, Leflunomide, Risedronate Sodium, and Benzydamine HCl to global pharmaceutical manufacturers from its WHO-GMP and ISO 9001 certified facility in Jammu, India.

Product overview

Anphar Laboratories is a WHO-GMP and ISO 9001 certified pharmaceutical company founded in 1987, specializing in the development, production, and export of Active Pharmaceutical Ingredients (APIs), impurities and working standards, and advanced drug intermediates. The company's product portfolio includes 25+ APIs across therapeutic categories such as Antipsychotics (Haloperidol, Amisulpride, Trifluoperazine, Fluphenazine, Prochlorperazine, Loxapine), Antidepressants (Paroxetine, Amoxapine), Antiemetics (Metoclopramide, Prochlorperazine), NSAIDs (Benzydamine), Anti-Histamines (Ebastine), DMARDs (Leflunomide), Bisphosphonates (Risedronate Sodium), and other specialty APIs. The company also offers Contract Research and Manufacturing Services (CRAMS) and R&D services for novel therapeutics development. Products are exported to 40+ countries worldwide including Europe, Latin America, Africa, and Asia.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) Portfolio High-quality Active Pharmaceutical Ingredients (APIs) across therapeutic categories including Antipsychotics (Haloperidol, Amisulpride, Trifluoperazine HCl, Fluphenazine Dihydrochloride, Prochlorperazine Maleate/Mesilate, Loxapine Succinate, Triflupromazine HCl), Antidepressants (Paroxetine HCl Hemihydrate, Anhydrous Paroxetine HCl, Fluvoxamine Maleate, Amoxapine), Antiemetics (Metoclopramide HCl Monohydrate, Prochlorperazine), NSAIDs (Benzydamine HCl), Anti-Histamines (Ebastine), DMARDs (Leflunomide), Bisphosphonates (Risedronate Sodium), Antispasmodics (Pinavarium Bromide), Diuretics (Amiloride HCl), Alpha-adrenergic agonists (Midodrine HCl), Antiulcer/GERD (Pantoprazole Sodium Sesquihydrate), Psychostimulants (Citicoline Sodium), and alcohol abstinence therapeutics (Acamprosate Calcium). Products are manufactured in IP/BP/USP/EP grades and supplied to global pharmaceutical manufacturers.
• Impurities and Working Standards Specialized pharmaceutical impurities and reference standards for quality control and drug safety verification, including Paroxetine impurities, Amiloride impurities, Fluvoxamine impurities, Haloperidol impurities, and Metoclopramide impurities. Supplied to pharmaceutical QC laboratories and manufacturers for testing and regulatory submissions.
• Advanced Drug Intermediates Specialized chemical intermediates for API synthesis, including Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate and 1-Benzyl-3-hydroxy-1H-indazole. Used to support both in-house API production and external pharmaceutical manufacturer needs worldwide.
• CRAMS (Contract Research and Manufacturing Services) Customized, efficient, and cost-effective contract research and manufacturing services delivered through state-of-the-art facilities and an experienced scientific team. Offered to pharmaceutical companies globally for custom synthesis and specialized manufacturing projects.
• Research and Development Services Cutting-edge R&D services focused on developing novel therapeutics and improving existing formulations to address unmet medical needs globally. Integrated with the company's process development and manufacturing capabilities.
• Quality Control Services In-house quality control laboratories equipped with HPLC and GC instruments for rigorous quality testing and regulatory compliance verification of APIs and intermediates.

Quantifiable outcome

• 35+ years of pharmaceutical manufacturing experience
• +1 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered minor.

• Coral LabsminorOthersPharmaceutical manufacturing customer sourcing Active Pharmaceutical Ingredients from Anphar for their drug formulation operations.
• Akums Drugs & PharmaceuticalsminorOthersIndian pharmaceutical company sourcing APIs from Anphar for their generic drug manufacturing operations.
• AL AndalousminorOthersRegional pharmaceutical distribution partner in Middle East/North Africa region sourcing APIs from Anphar.
• Medicamen Biotech LtdminorOthersIndian pharmaceutical biotechnology company sourcing Active Pharmaceutical Ingredients from Anphar.
• Nabi QasimminorOthersPharmaceutical company sourcing APIs from Anphar for regional drug manufacturing.
• Square PharmaceuticalsminorOthersMajor Bangladeshi pharmaceutical company sourcing APIs from Anphar for their extensive generic drug portfolio.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Laurus Labs: Indian pharmaceutical company with strong API and CRAMS operations. Comparable B2B pharmaceutical manufacturing model with broader therapeutic category coverage and a larger capital base, providing a benchmark for Anphar's growth trajectory.
• Granules India: Indian pharmaceutical manufacturer with significant API operations and formulations. Comparable in B2B API supply model and global export presence, though broader in scope and range of offerings.
• Jubilant Pharmova: Indian pharmaceutical company with API and CRAMS operations serving global markets. Comparable in pharmaceutical manufacturing capacity, regulatory standards, and customer base of international drug manufacturers.
• Divis Laboratories: Large Indian API and CRAMS major with extensive global operations. While significantly larger, Divis operates in the same small-molecule API space and serves many of the same generic pharmaceutical manufacturers that Anphar targets.
• Piramal Pharma Solutions: Major Indian CRAMS provider serving global pharmaceutical companies. Comparable to Anphar's CRAMS offering, though at significantly larger scale and with broader service capabilities including biologics.

Direct peers

• Shilpa Medicare: Indian API and formulation manufacturer with established exports to global markets. Similar in scale and customer base to Anphar, with comparable offerings in APIs across multiple therapeutic categories.
• Aurobindo Pharma: Leading Indian manufacturer of generic APIs and formulations with a large global export footprint. Direct competitor to Anphar in generic small-molecule APIs, particularly in CNS and other therapeutic categories, with similar B2B pharmaceutical supply model.
• Aarti Drugs: Indian API manufacturer with a portfolio spanning multiple therapeutic categories including anti-inflammatory, antihistamine, and CNS molecules. Highly comparable to Anphar in scale, customer base (generic pharma manufacturers), and B2B API supply model.
• Neuland Laboratories: Indian API and CRAMS provider serving global pharmaceutical manufacturers. Direct peer in small-molecule API manufacturing with similar CRAMS offerings and customer segments, including specialty and legacy molecule focus.
• Ipca Laboratories: Indian pharmaceutical company with significant API manufacturing operations across therapeutic categories. Comparable to Anphar in API manufacturing capabilities, export focus, and customer base of global generic drug manufacturers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php?id=61566209408573
• LinkedInlinkedin.com/company/anphar-laboratories-pvt-ltd
• Instagraminstagram.com/anphar.labs?igsh=Ym0zYXYzMzU5cnpi

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anphar Laboratories